Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone Extension for Resistant Schizophrenia
NCT00143351Phase 3Completed
- Sponsor
- Viatris
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ziprasidone in schizophrenia, sponsored by Viatris. Primary endpoint: Long-term efficacy of oral Ziprasidone in maintenance treatment. Started Jun 2003; status: completed.
02
Drugs
ziprasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00143351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143351.